Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Journal of the American Chemical Society
|
September 24, 2004
Oligothiophene isocyanides for platinum-based molecular electronic applications
Dennis Bong, Iris Tam, Ronald Breslow
The American Journal of Managed Care
|
February 14, 2023
Evolving considerations for choice of hepatitis B vaccine
Dalga D Surofchy, Neil Shieh, Iris Tam
Organic Letters
|
September 12, 2003
A forbidden rearrangement
Martin Leivers, Iris Tam, Kevin Groves, et al.
Journal of Managed Care & Specialty Pharmacy
|
August 28, 2022
Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease
Darrell E White, Laura H Hendrix, Lucille Sun, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 10, 2022
Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease
Denise M Visco, Laura H Hendrix, Lucille Sun, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Journal of the American Chemical Society
|
September 24, 2004
Oligothiophene isocyanides for platinum-based molecular electronic applications
Dennis Bong, Iris Tam, Ronald Breslow
The American Journal of Managed Care
|
February 14, 2023
Evolving considerations for choice of hepatitis B vaccine
Dalga D Surofchy, Neil Shieh, Iris Tam
Organic Letters
|
September 12, 2003
A forbidden rearrangement
Martin Leivers, Iris Tam, Kevin Groves, et al.
Journal of Managed Care & Specialty Pharmacy
|
August 28, 2022
Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease
Darrell E White, Laura H Hendrix, Lucille Sun, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 10, 2022
Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease
Denise M Visco, Laura H Hendrix, Lucille Sun, et al.
Page
of 1